ONGOING CLINICAL TRIALS
The
gold standard for clinical interventions is the randomised controlled trial.
This page provides a list of trials currently in progress trials.
1. TREATMENT OF IgA NEPHROPATHY WITH ANGIOTENSIN CONVERTING ENZYMES INHIBITORS (ACE-I): DESIGN OF A PROSPECTIVE RANDOMIZED MULTICENTER TRIAL. Torino, Italy
2. THERAPEUTIC MULTICENTER TRIAL (STEROIDS ALONE VS STEROIDS PLUS AZATHIOPRINE) IN IgAN PATIENTS. Lecco, Italy
4. A RANDOMIZED CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL (MMF) IN PATIENTS WITH IGA NEPHROPATHY Dallas, TX, USA
Many
groups are interested in new trials to find out the best treatment for IgAN.
We knew some of them only. If you are doing a prospective randomized control
trial, please download, fill in the 
,
send it to the webmaster
and we will be pleased to include your trial in this short list
1. TREATMENT OF IgA NEPHROPATHY WITH ANGIOTENSIN CONVERTING ENZYMES INHIBITORS (ACE-I): DESIGN OF A PROSPECTIVE RANDOMIZED MULTICENTER TRIAL
COORDINATOR
Rosanna Coppo MD
Assistants: Licia Peruzzi, Sandro Amore, Monica Chiesa, Paola Cirina
FROM Nephrology, Dialysis and Transplantation Unit
Regina Margherita University Hospital
P Polonia 94,
CITY/ COUNTRY Torino, 10126, Italy
E-MAIL nefrologia@oirmsantanna.piemonte.it
FAX +39-011-6635543
REFERENCE Angiotensin-converting enzyme inhibitors (ACE-Is) in young patients with IgA nephropathy: effects against deterioration of renal function (European Biomed project EEC Concerted Action BMH4-97-2487 (OG 12-SSMI) Biomedicine and Health Research, (Nephrol Dial Transplant 1999;14:840-841) [PDF]
Acronym: IgACE
2. THERAPEUTIC MULTICENTER TRIAL (STEROIDS ALONE VS STEROIDS PLUS AZATHIOPRINE) IN IgAN PATIENTS
COORDINATOR Claudio Pozzi (Francesco Locatelli, Claudio Ponticelli, Paolo Altieri)
FROM:
FULL POSTAL ADDRESS
Nephrology and Dialysis Department, “A. Manzoni” Hospital, via
dell’Eremo 9, 23900 Lecco
CITY/ COUNTRY Lecco/Italy
E-MAIL nefrologia@ospedale.lecco.it
FAX +39-0341-489860
3. ONE-YEAR ANGIOTENSIN-CONVERTING ENZYME INHIBITION
PLUS MYCOPHENOLATE MOFETIL IMMUNOSUPPRESSION (AIM) IN THE COURSE OF EARLY
IgA NEPHROPATHY: A MULTICENTRE, RANDOMISED, CONTROLLED, STUDY.
COORDINATOR
Prof. Antonio Dal Canton MD
FROM Nephrology, Dialysis and Transplantation
IRCCS Policlinico S. Matteo
P.le Golgi 2, 27100 Pavia, Italy
CITY/ COUNTRY Pavia / Italy
E-MAIL dalcanton@mbox.medit.it
FAX 0039 0382 52 6341
REFERENCE Research protol for the treatment of the IgA nephropathy
TEXT OF PROTOCOL
Title
One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil
immunosuppression (AIM) in the course of early IgA nephropathy: A multicentre,
randomised, controlled, study.
Acronym
The AIM IgAN study.
Study
code
AIM 1
4. A RANDOMIZED CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL (MMF) IN PATIENTS WITH IGA NEPHROPATHY
COORDINATOR
Ronald J. Hogg, MD
Assistants: Dana Parrott, Shelley Long, Jeannette Lee, PhD
FROM SPNSG
Medical City Dallas Hospital
7777 Forest Lane Suite C-740
Dallas, Texas 75230
E-mail: spnsg@lonestarhealth.com
REFERENCE
American Journal of Kidney Diseases 1995; 26: 792-6
Full
Text Protocol
Website: www.spnsg.org
Acronym: MMF/IgAN Study
5. PROSPECTIVE RANDOMIZED CONTROLLED MULTICENTER TRIAL ON STEROIDS PLUS RAMIPRIL IN PROTEINURIC IGA NEPHROPATHY
COORDINATOR
C. Manno
Assistants: Gesualdo L, D'Altri C, Rossini M, Grandaliano G, Schena FP
FROM Department of Emergency and Organs Transplantation, University of Bari,
Italy
E-mail: c.manno@nephro.uniba.it
REFERENCE
Prospective randomized controlled multicenter trial on steroids plus ramipril
in proteinuric IgA nephropathy.
J Nephrol 2001 Jul-Aug;14(4):248-52
Full
Text Protocol
